Aardvark Therapeutics (AARD) Net Income towards Common Stockholders (2024 - 2026)
Aardvark Therapeutics (AARD) reported Net Income towards Common Stockholders of -$21.6 million for Q1 2026, down 132.09% on a YoY basis from $67.2 million in Q1 2025, and down 22.73% sequentially from -$17.6 million in Q4 2025.
Aardvark Therapeutics (AARD) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$21.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 132.09% year-over-year to -$21.6 million; the trailing twelve-month figure through Mar 2026 stood at -$69.9 million (down 127.08% YoY), and the FY2025 full-year result was -$69.9 million, down 80.24% from the prior year.
- Net Income towards Common Stockholders fell to -$21.6 million in Q1 2026, from -$17.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.1 million in Q1 2024 to a low of -$21.6 million in Q1 2026.
- A 3-year average of -$11.4 million and a median of -$11.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 47.62% in 2025, while the deepest fall reached 349.52% in 2025.
- Tracing AARD's Net Income towards Common Stockholders over 3 years: stood at -$11.9 million in 2024, then tumbled by 47.62% to -$17.6 million in 2025, then decreased by 22.73% to -$21.6 million in 2026.
- Business Quant data shows AARD's Net Income towards Common Stockholders at -$21.6 million in Q1 2026, -$17.6 million in Q4 2025, and -$16.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | -0.68 |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Aardvark Therapeutics | 138.83 Mn | 18.86 Mn | - | -21.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.58 Mn |
| Dec 31, 2025 | -17.58 Mn |
| Sep 30, 2025 | -16.35 Mn |
| Jun 30, 2025 | -14.38 Mn |
| Mar 31, 2025 | -9.30 Mn |
| Dec 31, 2024 | -11.91 Mn |
| Sep 30, 2024 | -4.09 Mn |
| Jun 30, 2024 | -5.48 Mn |
| Mar 31, 2024 | -2.07 Mn |